EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of a Nomogram for Predicting Pathological Upgrading in Men With Biopsy Gleason 3 + 3 Prostate Cancer Undergoing Radical Prostatectomy: A Population‐Based Study

Han Li iD, Shuaitao Xiong, Miao Wang, Ming Liu iD, Jianye Wang, Jiawen Wang, Zhengtong Lv iD

The Prostate · 2026

DOI: 10.1002/pros.70126 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Prostate, 2026. Verfasst von Han Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Pekin…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Nomograms, Prostatectomy, Adenocarcinoma. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Innovation Funds for National High Level Hospital Clinical Research Funding, Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pathological upgrading after surgery is common among men with biopsy Gleason score (GS) 3 + 3 prostate cancer who undergo radical prostatectomy and may impact prognosis, highlighting the need for preoperative risk identification. This study aimed to develop and internally validate a predictive nomogram for pathological upgrading in this surgically treated population.

Methods

Patients aged ≥ 18 years with biopsy GS 3 + 3 prostate adenocarcinoma who underwent radical prostatectomy between 2004 and 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 14,484 patients were included and randomly divided into a training cohort and a validation cohort in a 7:3 ratio. Multivariable logistic regression was used to construct a prediction model based on preoperative clinical variables. Model performance was assessed using discrimination, calibration, and decision curve analysis. Internal validation was performed using bootstrap resampling and 10‐fold cross‐validation. Survival differences between risk groups defined by the nomogram were evaluated using Kaplan–Meier analysis.

Results

Overall, 47.9% of patients experienced pathological upgrading to a radical prostatectomy GS of 3 + 4 or higher. Age, prostate‐specific antigen (PSA) level, number of positive biopsy cores, and clinical T stage were independently associated with upgrading and were incorporated into the final nomogram. The model demonstrated moderate discrimination, with an area under the curve (AUC) of 0.663 (95% CI, 0.652–0.673) in the training cohort and 0.648 (95% CI, 0.632–0.664) in the validation cohort. Bootstrap internal validation yielded an optimism‐corrected C‐statistic of 0.662. Calibration was satisfactory, and Brier scores were 0.228 in the training cohort and 0.231 in the validation cohort. In exploratory, unadjusted analyses, patients classified as high risk by the nomogram had significantly lower overall survival than those in the low‐risk group.

Conclusions

The nomogram demonstrated moderate predictive performance for pathological upgrading in men with biopsy GS 3 + 3 prostate cancer who were selected for radical prostatectomy, and may assist in individualized preoperative decision‐making within this surgical population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNomogramsProstatectomyAdenocarcinomaHumansMaleNeoplasm GradingAgedMiddle AgedSEER ProgramPrognosisBiopsy

Stichwörter der Autor:innen

Gleason scoreSEER databasenomogrampathological upgradingprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Peking University Fifth School of Clinical Medicine, Beijing, China.
  • Departmentof Urology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.

ORCID-Profile: Han Li, Ming Liu, Zhengtong Lv

Förderung

  • Innovation Funds for National High Level Hospital Clinical Research Funding
  • Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Zitieren

APA

Li, H., Xiong, S., Wang, M., Liu, M., Wang, J., Wang, J., & Lv, Z. (2026). Development and Validation of a Nomogram for Predicting Pathological Upgrading in Men With Biopsy Gleason 3 + 3 Prostate Cancer Undergoing Radical Prostatectomy: A Population‐Based Study. The Prostate. https://doi.org/10.1002/pros.70126

Vancouver

Li H, Xiong S, Wang M, Liu M, Wang J, Wang J, et al. Development and Validation of a Nomogram for Predicting Pathological Upgrading in Men With Biopsy Gleason 3 + 3 Prostate Cancer Undergoing Radical Prostatectomy: A Population‐Based Study. The Prostate. 2026. doi:10.1002/pros.70126

BibTeX
@article{Li2026,
  author = {Li, Han and Xiong, Shuaitao and Wang, Miao and Liu, Ming and Wang, Jianye and Wang, Jiawen and Lv, Zhengtong},
  title = {Development and Validation of a Nomogram for Predicting Pathological Upgrading in Men With Biopsy Gleason 3 + 3 Prostate Cancer Undergoing Radical Prostatectomy: A Population‐Based Study},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70126}
}
Kostenlos starten →